Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (2611)	11/3/1997 9:50:00 PM
From: Joe E.	Respond to of 6136

Re: Here's a big new market - People without AIDS. I seem to recall that protease inhibitors anre not included in this regimen. Am I wrong? Answering my own question (PI's are not included): From CDC summaries "Title: 'Morning After' Pill for AIDS Authors: Wasowicz, Lidia Source: United Press International (03/03/97) Abstract: A study to test the efficacy of "morning-after" drug therapy for people who are accidentally exposed to HIV is slated to begin soon in San Francisco. As part of the trial, researchers at the San Francisco General Hospital will recruit individuals exposed to HIV as the result of one incident of risky behavior. The study participants will receive a 30-day supply of AZT and 3TC, with the hope that the treatment may prevent the virus from taking hold. HIV prevention advocates warn that the therapy could reverse the trend toward safe behaviors, but researchers say the strategy is worthwhile. Studies of similar preventive therapy for health care workers who are accidentally exposed to HIV on the job have shown that the drugs dramatically reduce the risk of infection. Major Descriptors: Exposure. Clinical trials. AZT. Health professionals. Risk reduction."